SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below a major psychological level have dominated discussion, with traders pointing to leveraged-position liquidations as adding to the pressure. The community is split between expectations of further downside amid risk-off and rate concerns and calls to buy an oversold dip.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas is drawing attention as its Phase 3 REGAL trial of GPS reaches final analysis after the 80th event, with topline results expected in November. Traders celebrated an after-hours jump and speculated about a data leak or short covering, while skeptics stressed that the results are still unknown and managements positive language does not establish success.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about business disruption and concern that the incident could damage trust. Traders debated whether it was a technical failure or a cyberattack, though hacking claims remained speculation, and many questioned why the shares held up amid the disruption.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is raising concerns about passive-fund selling and pressure on the stock, while Bitcoins decline is adding to the weakness. Traders disagree on whether the index impact is already priced in, with bearish forced-selling concerns countered by dip-buying and hopes for a rebound.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention after a sharp selloff tied to a Q3 revenue miss and the lack of detailed guidance, with traders debating cash burn, possible dilution, and managements communication. Optimism about the BCG-naive trial results, a planned FDA filing, expanded Anktiva access, and sepsis studies is countered by concern that commercial growth may not keep pace with expectations.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff has XRP sliding toward key support, with traders pointing to Bitcoin-led market weakness, inflation and rate-hike concerns, and leveraged liquidations. The community is split between holders accumulating the dip and bearish traders warning of more downside, while some also cite Ripple-related token supply and fading regulatory hopes.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

FDA discussions over assay refinement pushed Candels planned prostate-cancer BLA filing to mid-2027, and traders are also concerned about potential dilution. The community is split between viewing this as a manufacturing and regulatory delay rather than a setback to the clinical data, and questioning managements credibility and execution.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,212,724.47747979. The last known price of Ethereum is 2,011.23339821 USD and is down -2.26 over the last 24 hours. It is currently trading on 14326 active market(s) with $10,433,558,649.69 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-market selloff, with traders pointing to inflation and hawkish rate expectations, Bitcoin weakness, and leveraged-position liquidations as pressure on prices. The community is divided between bearish calls for further losses and buyers treating the decline as an oversold opportunity, while key support levels are closely watched.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure as CEO amid reports of a personal scandal has sparked concern about Nvidias leadership transition, with Colette Kress serving as interim CEO. Traders are divided between fears that the company may struggle without Huang and views that its business can withstand the change, with some buying the selloff ahead of earnings.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins sharp decline and broader weakness in crypto-linked stocks are weighing on Coinbase, with traders focused on its repeated lows and whether the selloff will continue. The discussion is predominantly bearish, though some see the stock as oversold or holding support and expect a rebound if crypto stabilizes.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Qureights Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule...

Contineum Therapeutics Reports Third-Quarter 2026 Financial Results

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results...

Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the...

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.

All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy

Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.read more...

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?

Equity

Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. 


Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its...

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and...

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Contineum Therapeutics Inc. - Ordinary Shares - Class A

Neutral Sentiment

<ul class="summary-bullets"><li>The miss is the second mid-stage setback for the same molecule in less than a year.</li><li>J&amp;J licensed PIPE-307 worldwide in 2023 in a deal that included $50 million upfront, a $25 million equity stake, more than $1 billion in potential milestones, and royalties.</li><li>J&amp;J is still reviewing exploratory measures and has not said whether it will continue development.</li></ul><p><br>Shares of Contineum Therapeutics (CTNM) fell about 10% in after-hours trading on Monday after the firm said that Johnson &amp; Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307 and licensed from Contineum, failed to meet its main goal in major depressive disorder.</p><p>The miss is the second mid-stage setback for the same molecule in less than a year and shifts more of Contineum’s story onto its unpartnered lung-disease program. JNJ stock traded flat after-hours at the time of writing.</p><h2 class="st-heading-2">What The Trial Tested And Missed</h2><p>MOONLIGHT-1 was a randomized, placebo-controlled proof-of-concept study of JNJ-5120/PIPE-307 as a stand-alone treatment in adults with major depression. The primary measure was change from baseline on the Montgomery-Åsberg Depression Rating Scale, a standard depression score, at Day 5 versus placebo. That bar was not met. The drug was well tolerated, with no new safety issues, Contineum said. J&amp;J is still reviewing exploratory measures and has not said whether it will continue development.</p><p>J&amp;J licensed PIPE-307 worldwide in 2023 in a deal that included $50 million upfront, a $25 million equity stake, more than $1 billion in potential milestones, and royalties.</p><h2 class="st-heading-2">A Second Miss For The Same Asset</h2><p>In November 2025, Contineum’s own mid-stage VISTA trial of PIPE-307 in relapsing-remitting multiple sclerosis also missed its primary and secondary goals. Shares sold off after that readout, and analysts already treated the depression study as high-risk. Two efficacy misses leave the program’s future in J&amp;J’s hands.</p><p>Investors now focus on PIPE-791, a drug Contineum is developing itself for idiopathic pulmonary fibrosis and chronic pain. PROPEL-IPF, a global mid-stage trial of about 324 patients, began dosing in the first quarter of 2026. It measures change in lung function over 26 weeks, has more than 55 sites in eight countries, and is not expected to finish until mid-2028. Contineum has deferred a progressive-MS effort for PIPE-791 and paused another early program, CTX-343.</p><p>Contineum’s cash was $236.6 million as of June 30, which the company says funds operations through mid-2029 — past the planned IPF readout.</p><h2 class="st-heading-2">How Did CTNM, JNJ Retail Traders React?</h2><p>On Stocktwits, retail sentiment around CTNM stock went from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume improved from ‘low’ to ‘normal’ levels.</p><p>Meanwhile, sentiment around JNJ stayed 'bearish.'</p><p>While <a href="https://stocktwits.com/symbol/CTNM">CTNM stock</a> has gained 30% year-to-date, <a href="https://stocktwits.com/symbol/JNJ">JNJ</a> gained 29%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srrk-shares-pull-back-after-fda-approval-for-genetic-disease-drug-but-wall-street-hikes-price-targets/cZtmh4bRBT3">SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Contineum Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. 

Johnson & Johnson

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Current Price	$9.78
Prev Close	$10.77
Open	$10.71
Dividend Yield	0.00%
50-Day Moving Average	$11.43
Beta	0.80
Avg. Volume	1.3M
PE Ratio	-5.53

52-Week High	$17.79
52-Week Low	$6.73
Market Capitalization	$422.89M
EPS (Annual)	-$2.17
Price to Book	1.56
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTNM Fundamentals